The sterility monitoring technology company has raised $25m in funding from investors including Hepalink, and will use the money to support global expansion.
Rapid Micro Biosystems, a US-based manufacturer of microbial detection technology to safeguard quality in pharmaceutical and personal care products, has raised $25m in a series C round featuring pharmaceuticals producer Hepalink USA.
Hepalink USA, a subsidiary of China-based Shenzhen Hepalink Pharmaceutical, was joined by Kleiner Perkins Caufield & Byers (KPCB), Longitude Capital, Quaker Partners, TPG Biotech and TVM Capital, as well as family office Richard K Mellon and Sons.
Rapid Micro’s Growth Direct System technology automatically monitors a pharmaceutical, medical…
